Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration in northeatern China

Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPR-16007956

Enrollment

Unknown

Registered

2016-02-20

Start date

2016-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious disease

Interventions

Small dose Intermittent bolus group:3000 mg, q12h

Large dose Intermittent bolus group:3000 mg, q8h

Extended infusion group:3000 mg, q8h, extended infusion 4 h

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients in the ICU, >=18 years; 2. Receiving CRRT; 3. Receiving cefoperazone/sulbactam with suspected or confirmed infections.

Exclusion criteria

Exclusion criteria: 1. Patients who had a suspected allergy to cephalosporin antibiotics; 2. Patients with end stage liver failure; 3. Patients who are pregnant; 4. Patients who are undergoing another clinical research; 5. Patients who have received cefoperazone/sulbactam before recruitment.

Design outcomes

Primary

Measure	Time frame
Vital signs;Blood;Blood biochemistry;Urine;sputum culture;	—

Countries

China

Contacts

Public ContactGao Chunlu

gao_chunlu@126.com+86 18644058369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026